
The AEGIS-II trial evaluated CSL112, a human apolipoprotein A1, in patients with acute myocardial infarction (MI). Although CSL112 did not reduce the primary endpoint through 90 days, a post-hoc analysis showed significant reductions in cardiovascular events (death, MI, or stroke) at 90, 180, and 365 days in patients with baseline LDL-C ≥100 mg/dL compared to placebo, suggesting that baseline LDL-C may influence the efficacy of CSL112.
Like
Save
Share